News FDA to Review ANI’s Request for Cortrophin Gel Use FDA to Review ANI’s Request for Cortrophin Gel Use by Somi Igbene, PhD | September 2, 2021 Share this article: Share article via email Copy article link The U.S. Food and Drug Administration (FDA) has agreed to review ANI Pharmaceuticals’ supplemental new drug application for the approval of Cortrophin Gel to treat people with multiple sclerosis (MS) and other chronic inflammatory conditions, including rheumatoid arthritis. Purified Cortrophin Gel (repository corticotropin injection USP) is a purified adrenocorticotropic hormone (ACTH) that works by stimulating the adrenal cortex to produce cortisol, corticosterone, and aldosterone, among others. These steroids help to reduce inflammation and more rapidly resolve disease relapses or flares. “FDA’s acceptance of our supplemental new drug application for Cortrophin Gel marks a significant milestone for ANI. With a Prescription Drug User Fee Act target action date of October 29, 2021 we are one step closer to bringing a much-needed product to patients and healthcare providers,” Nikhil Lalwani, CEO of ANI Pharmaceuticals, said in a press release. Recommended Reading August 20, 2021 Columns by Jamie Hughes Celebrity or Not, You Matter to the MS Community “We look forward to further productive engagement with the FDA, and in parallel, we are focused on preparations for the launch of Cortrophin Gel,” Lalwani added. The FDA originally approved Cortrophin Gel in 1954 for the treatment of several autoimmune conditions, including MS, rheumatoid arthritis, and nephrotic syndrome, but it was last used in the 1980s. ANI Pharmaceuticals acquired Cortrophin Gel from Merck in early 2016 and spent more than four years validating the therapy and modernizing its manufacturing and control processes to align with current FDA standards. After completing the revalidation process in March 2020, ANI sought FDA approval to reintroduce the therapy in the U.S. market. However, in April 2020, the FDA rejected the request, citing concerns with the quality of information provided about the therapy’s chemistry, manufacturing, and control processes. ANI addressed the concerns highlighted in the refusal letter by the FDA and resubmitted the application, which the agency has now accepted for review. Marketed as Acthar Gel, corticotropin is currently made available only by Mallinckrodt Pharmaceuticals. The re-introduction of ANI’s Cortrophin Gel would provide treatment options for people with chronic autoimmune disorders. “The availability of a second corticotropin or ACTH-based treatment is meaningful for patients struggling with the devastating consequences of chronic autoimmune disorders, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome,” said Chris Mutz, chief commercial officer and head of rare diseases at ANI Pharmaceuticals. The FDA will now review ANI’s supplemental new drug application and decide by Oct. 29 if the submission for Cortrophin Gel is complete and suitable for approval. Print This Page About the Author Somi Igbene, PhD Somi graduated from Imperial College London in 2011 with a PhD in cellular and molecular immunology. She worked as a medical writer at several medical communications agencies in London, including Core Medica. Besides science writing, Somi works as a registered associate nutritionist, helping adults and children improve their diets to prevent type 2 diabetes. Tags ACTH, autoimmune disorders, Cortrophin Gel, FDA
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression
